Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia

Salvaris, R. orcid.org/0000-0003-1053-5503, Mulligan, S. orcid.org/0000-0003-1928-2098, Puig, A. orcid.org/0000-0002-7730-6310 et al. (2 more authors) (2023) Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia. Internal Medicine Journal, 53 (11). pp. 2115-2118. ISSN 1444-0903

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. https://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: Australia; Bruton tyrosine kinase (BTK) inhibitors; chronic lymphocytic leukaemia; ibrutinib; proton pump inhibitor (PPI); real-world evidence; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proton Pump Inhibitors; Neoplasm Recurrence, Local; Australia; Protein Kinase Inhibitors
Dates:
  • Submitted: 22 March 2023
  • Accepted: 20 August 2023
  • Published (online): 11 November 2023
  • Published: November 2023
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Clinical Dentistry (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 19 Jan 2024 11:52
Last Modified: 19 Jan 2024 11:52
Status: Published
Publisher: Wiley
Refereed: Yes
Identification Number: https://doi.org/10.1111/imj.16267
Related URLs:

Export

Statistics


CORE (COnnecting REpositories)